Ridgeway Capital Partners logo

Ridgeway Capital Partners

Asia, Tokyo, Japan, Tokyo

Description

Ridgeway Capital Partners Ltd. is a professional firm that specializes in private equity investments. Comprised of Japanese professionals

Investor Profile

Ridgeway Capital Partners has made 2 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series Unknown (50%)
  • Series C (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Transportation
  • Biotechnology
  • Health Care
  • Health Diagnostics
  • Oncology
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Ridgeway Capital Partners frequently co-invest with?

Ridgeback Capital
North America, New York, United States, New York
Co-Investments: 1
Quassar Capital
North America, New York, United States, New York
Co-Investments: 1
Goldman Sachs
North America, New York, United States, New York
Co-Investments: 1
SBVA
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
Aju IB Investment
Asia, Seoul-t'ukpyolsi, South Korea, Yeoksamdong
Co-Investments: 1
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 1
VV
Europe, Moscow City, Russian Federation, Moscow
Co-Investments: 1
Redmile Group
North America, California, United States, San Francisco
Co-Investments: 1
Jennison Associates
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by Ridgeway Capital Partners?

AWR Logistics

Texas, South Carolina, United States

AWR Logistics is a freight broker based 3PL company that provides transportation services for shippers and carriers.

Transportation
Series UnknownOct 12, 2014
Amount Raised: $7,800,000
Bellicum Pharmaceuticals

Houston, Texas, United States

Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company that is driving the future of cellular immuno-oncology (IO).

BiotechnologyHealth CareHealth DiagnosticsOncologyTherapeutics
Series CAug 27, 2014
Amount Raised: $55,000,000